Xacduro
Payments companies reported to CMS as associated with Xacduro. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Xacduro, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Xacduro
These are the largest totals companies reported as associated with Xacduro. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Juan Diaz | Altamonte Springs, FL | Infectious Disease | $18,997.81 |
| Michael Gelfand | Memphis, TN | Infectious Disease | $12,739.99 |
| Fares Khater | Whitesburg, KY | Internal Medicine | $10,225.47 |
| Rajkumar Dasgupta | Pasadena, CA | Pulmonary Disease | $10,015.81 |
| Jason Sniffen | Altamonte Springs, FL | Infectious Disease | $7,435.13 |
| Edward Dominguez | Dallas, TX | Infectious Disease | $6,967.48 |
| Louis Guzzi | Orlando, FL | Critical Care Medicine (Anesthesiology) | $6,907.20 |
| Christian Sandrock | Sacramento, CA | Internal Medicine | $6,048.00 |
| Charles Rose | Lexington, KY | Infectious Disease | $5,228.80 |
| George Sakoulas | San Diego, CA | Infectious Disease | $5,143.48 |
Prescribed Xacduro?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.